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and store such a large amount of cholesterol indicates that 
there is a close link between the evolution of the nervous 
system and a specifi c role for cholesterol. Within the brain, 
some 70% of cholesterol is present in myelin, where it fulfi lls 
a critical insulating role. It is likely that the requirement 
for effi cient signaling despite a small transverse diameter 
of axons was a key selective pressure driving the accretion 
of cholesterol in the mammalian brain ( 1, 2 ). The require-
ment for large amounts of cholesterol is further under-
scored by the long half-life of brain cholesterol; overall 
brain cholesterol turns over some 250–300 times slower than 
that in the circulation ( 3 ). 
 At a cellular level, the myelin sheath consists of sections 
of plasma membrane repeatedly wrapped around an axon, 
with the extrusion of virtually all of the cytoplasm. Myelin 
is formed by 2 very specialized cells: the oligodendrocyte 
in the central nervous system (CNS) and the Schwann cell 
in the peripheral nervous system (PNS). Because an indi-
vidual axon may be ensheathed by myelin from several oli-
godendrocytes, periodic gaps are present in the sheath. 
These are called the “nodes of Ranvier” and are the site of 
propagation of the action potential. Myelin can thus be 
regarded as a discontinuous insulation that enables the sal-
tatory conduction of the action potential ( 1, 2 ). In addition 
 Abstract  Cholesterol is an essential component of both the 
peripheral and central nervous systems of mammals. Over 
the last decade, evidence has accumulated that disturbances 
in cholesterol metabolism are associated with the develop-
ment of various neurological conditions. In addition to ge-
netically defi ned defects in cholesterol synthesis, which will 
be covered in another review in this Thematic Series, defects 
in cholesterol metabolism (cerebrotendinous xanthomatosis) 
and intracellular transport (Niemann Pick Syndrome) lead to 
neurological disease. A subform of hereditary spastic paresis 
(type SPG5) and Huntington’s disease are neurological 
diseases with mutations in genes that are of importance for 
cholesterol metabolism. Neurodegeneration is generally as-
sociated with disturbances in cholesterol metabolism, and 
presence of the E4 isoform of the cholesterol transporter 
apolipoprotein  E as well as hypercholesterolemia are impor-
tant risk factors for development of Alzheimer’s disease.  
 In the present review, we discuss the links between genetic 
disturbances in cholesterol metabolism and the above neuro-
logical disorders. —Björkhem, I., V. Leoni, and S. Meaney. 
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 THE ROLE OF CHOLESTEROL AND ITS TURNOVER 
IN THE NERVOUS SYSTEM 
 The mammalian nervous system contains a dispropor-
tionate amount of cholesterol. In the brain, the choles-
terol content is about 10-fold greater than in any other 
organ ( 1 ). The development of the capacity to synthesize 
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which is able to pass across the blood-brain barrier and 
enter the circulation ( 3, 8, 9 ). In addition, there is a small 
effl ux of cholesterol from the brain in the form of apolipo-
protein (APO) E containing lipoproteins via the cerebro-
spinal fl uid ( 10 ). The mechanism by which cholesterol is 
eliminated from the PNS is not known with certainty, and 
the spinal cord does not appear to be able to synthesize 
24S-OHC. 
 The stability of the bulk of cholesterol in the CNS and in 
the spinal cord is in marked contrast to the rapidly chang-
ing levels of plasma lipoproteins under different conditions. 
The turnover of the cholesterol present in membranes of 
the neuronal cells and in astrocytes may, however, change 
in response to different factors. Under normal conditions, 
cholesterol 24-hydroxylase (CYP46A1), the enzyme system 
responsible for formation of 24S-OHC, is present only in 
neuronal cells, with particularly high levels in the pyramidal 
neurons in various layers of the cortex, in the hippocam-
pus, and in Purkinje cells in the cerebellum ( 9 ). The up-
take of cholesterol by these cells may thus be balanced by 
the secretion of 24S-OHC. The 24S-OHC secreted from 
the neuronal cells may be of importance for regulation of 
cholesterol synthesis and secretion of this cholesterol in 
APOE-bound form from astroglia. The latter effects may 
be mediated by the liver X receptor (LXR) ( 5, 11 ). 
 In the liver, the conversion of cholesterol into bile acids 
is regulated by highly sophisticated mechanisms ( 12 ). In 
the brain, however, the expression of CYP46A1 appears to 
be resistant to regulatory axes, which are known to regu-
late cholesterol homeostasis and bile acid synthesis ( 13 ). 
Indeed, the putative promoter region of CYP46A1 has the 
characteristics of a housekeeping gene ( 13 ), although re-
cent data indicate that epigenetic mechanisms may regu-
late CYP46A1 expression ( 14, 15 ). In contrast, cholesterol 
synthesis appears to be regulated by similar mechanisms 
both outside and inside the brain, with hydroxy-methyl-
glutaryl CoA reductase (HMGCR) being the most impor-
tant regulatory enzyme ( 2 ). However, in the brain, cholesterol 
synthesis via the 7-dehydrodesmosterol pathway seems to 
be preferred over the 7-dehydrocholesterol pathway, and 
disruption of the gene coding for the   24-reductase re-
sults in the accumulation of desmosterol without any ac-
cumulation of 7-dehydrodesmosterol ( 16 ). 
 In the Cyp46a1 null mouse, loss of the main pathway for 
cholesterol elimination results in a compensatory 40% de-
crease in cholesterol synthesis, while the overall content of 
brain cholesterol is normal. There are, however, signifi cant 
behavioral changes and reduced memory function, indi-
cating that a certain rate of fl ux through the mevalonate 
pathway is necessary to support memory consolidation 
( 17 ). In subsequent studies, the isoprenoid geranylgera-
niol was identifi ed as the important intermediate, and it 
was suggested the Cyp46a1-mediated removal of choles-
terol from neurons is critical to prevent cholesterol accumu-
lation, feedback inhibition of cholesterol synthesis, and a 
decreased production of essential isoprenoid intermediates 
[reviewed in ( 9 )]. 
 Although formation of 24S-OHC is responsible for the 
removal of about two-thirds of cholesterol from the brain, 
to a large lipid component, myelin also contains many spe-
cifi c proteins such as proteolipid protein and myelin basic 
protein. Recently, evidence has been presented that cho-
lesterol can regulate the correct targeting of one of the 
major membrane proteins of the PNS and thereby myelin 
compaction. These data extend the role of cholesterol in 
myelin from an essential structural component to a regula-
tor of overall myelin structure ( 4 ). 
 The remaining 30% of brain cholesterol is divided be-
tween glial cells (20%) and neurons (10%). According to 
various in vitro studies with cultured cells, astrocytes syn-
thesize at least 2- to 3-fold more cholesterol than neurons, 
and oligodendrocytes have an even higher capacity for cho-
lesterol synthesis, at least during periods of active myelina-
tion [for a more detailed review, see ref ( 3 )]. It has also been 
suggested that in the mature state, the neurons synthesize 
only a relatively small amount of cholesterol, and instead 
they rely almost totally on the supply of cholesterol from 
glial cells, especially astrocytes in the CNS ( 5 ). Studies using 
conditional ablation of a key gene in cholesterol synthesis 
have provided evidence that at least some adult neurons can 
survive without any de novo cholesterol synthesis ( 6, 7 ). 
 It is noteworthy that even minor changes in the struc-
ture of the constituent sterols of the nervous system, e.g., the 
presence of one additional double bond, leads to a change 
in the biophysical properties of the cell membrane with 
profound clinical effects. This is illustrated by the severity 
of the neurological phenotypes associated with defects 
in cholesterol synthesis, which lead to the incorporation of 
a cholesterol precursor such as desmosterol or 7-dehydro-
cholesterol into cell membranes. For a detailed review, see 
the review from Porter in this Thematic Series. 
 In the cells outside the CNS, the overall cholesterol 
homeostasis is achieved by de novo synthesis, uptake of 
lipoprotein-bound cholesterol, and effl ux of cholesterol. 
In addition to this, liver can eliminate cholesterol by con-
version into polar bile acids. When challenged with high 
levels of exogenous cholesterol, the excess can be stored 
in an esterifi ed form. 
 The strategy used by nature for cholesterol homeostasis 
in the brain and spinal cord is different from that in other 
parts of the body. Due to the effi cient blood-brain barrier, 
there is no passage of lipoprotein-bound cholesterol from 
the circulation to the brain ( 1, 3 ). The blood-brain barrier 
thus prevents diffusion of large molecules at the level of 
tight junctional attachments between adjacent capillary 
endothelial cells. In addition to this, there is also no trans-
vesicular movement of solution across the capillaries. It is 
possible that one or more members of the ATP binding 
cassette transporter superfamily may be involved in the ex-
clusion of circulating cholesterol from the brain, but con-
clusive evidence is lacking for this. 
 Thus, all the cholesterol present in the brain is formed 
by de novo synthesis, and the same is true also for the cho-
lesterol in the PNS. Except for the active phase of specifi c 
pathological conditions, almost all (at least 99%) choles-
terol in the nervous system is unesterifi ed. In the adult brain, 
most of its synthesis is balanced by formation of a hydroxy-
lated metabolite, 24S-hydroxycholesterol (24S-OHC), 
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the balance between 24S-OHC and 27-OHC in the brain is 
of importance for neurodegeneration ( 28, 29 ). In light of 
the importance of an adequate fl ux of intermediates 
through the mevalonate pathway, the entry of an inhibi-
tory compound into the brain may have deleterious down-
stream consequences for cognition. 
 DEFECTS IN CHOLESTEROL SYNTHESIS 
 In view of the importance of cholesterol, it is not surpris-
ing that relatively few disorders in the synthesis of this mol-
ecule are compatible with life. The disorders are associated 
with accumulation of a cholesterol precursor (lathosterol, 
desmosterol, or 7-dehydrocholesterol) and severely debili-
tating and frequently fatal birth defects. For a detailed re-
view, see the review from Porter in this Thematic Series. 
 Cerebrotendinous xanthomatosis 
 The patients are characterized by dementia, ataxia, cat-
aracts, and xanthomas in the tendons and in the nervous 
system. Typical onsets of the disease consists of early bilat-
eral cataracts and diarrhea, followed by cerebellar and py-
ramidal signs, mental retardation, and xanthomas. 
 In contrast to the situation in familial hypercholesterol-
emia, the xanthomas contain high levels of cholestanol, 
the 5  -saturated analog of cholesterol. 
 This rare autosomal recessive genetic disorder is caused 
by a mutation in CYP27A1 that encodes the cytochrome 
P-450 enzyme sterol 27-hydroxylase [for reviews, see ( 30, 
31 )]. The gene contains nine exons and spans 18.6 kb of 
DNA. The enzyme comprises 498 amino acids and con-
tains putative binding sites for heme ligands and adreno-
doxin. CYP27A1 is located at the inner mitochondrial 
membranes. 
 CYP27A1 is important for the normal oxidation of the 
steroid side-chain in connection with biosynthesis of bile 
acids ( 12 ) and is the rate limiting step in the conversion of 
the C27-steroid into a C24-steroid. The preferred sub-
strates for the enzyme are thus 7  -hydroxylated intermedi-
ates in bile acid synthesis. The enzyme is, however, also 
active on cholesterol. Because the enzyme is likely to be 
present and active in most cells in the body, and all cells 
under normal conditions, APOE seems to be the most im-
portant carrier of cholesterol in the brain extracellular 
fl uid. In view of this, it is surprising that deletion of APOE 
does not appear to lead to any major functional abnor-
malities in the brain, although there is a compensatory 
increase in the expression of APOD ( 18 ). In aged APOE 
knockout mice, however, there is a lipid deposition in as-
trocytes in hippocampus and thalamus ( 19 ). In addition to 
APOE and APOD, there are other apolipoproteins in the 
brain, such as APOJ (also known as clusterin) and APOA1, 
that may be of importance ( 3 ). 
 THE ROLE OF O XYSTEROLS 
 Side-chain oxidized oxysterols (SCOx) such as 24S-OHC 
have the capacity to traverse biological membranes, and 
there is a concentration-driven fl ux of this oxysterol from 
the brain into the circulation ( 20 ). This fl ux corresponds 
to an elimination of 6–7 mg cholesterol/24 h ( 3 ). The ox-
ysterol is taken up by the liver and further oxidized to bile 
acids ( 8 ). In addition to the role of 24S-OHC in the elimi-
nation of cholesterol, it may be of importance in connec-
tion with neurodegeneration. Under in vitro conditions, 
this oxysterol stimulates   -secretase activity and inhibits 
  -secretase activity in neuronal cell lines ( 21–23 ). This is 
consistent with a preventive effect of 24S-OHC on genera-
tion of amyloid. In accordance with this, it was recently 
reported that injection of adeno-associated vector encod-
ing CYP46A1 in the cortex and hippocampus of amyloid 
precursor protein (APP)-mutated mice before the onset of 
amyloid deposits markedly reduced these deposits ( 24 ). In 
addition, the treatment caused improvement in spatial 
memory. Further support for the contention that increased 
formation of 24S-OHC is benefi cial was presented in a very 
recent report demonstrating that disruption of the gene 
coding for the esterifi cation enzyme ACAT1 in a mouse 
model of Alzheimer’s disease (AD) had a benefi cial effect 
on amyloid generation and memory function ( 25 ). Evi-
dence was given that at least part of this effect was medi-
ated by increased levels of 24S-OHC. 
 A related SCOx, 27-hydroxycholesterol (27-OHC), has 
similar physiochemical properties to 24S-OHC and is also 
able to pass the blood-brain barrier. There is only a low 
production of this oxysterol in CNS, and most of the 27-
OHC present in the brain and cerebrospinal fl uid origi-
nates from extracerebral sources. Although there is a 
substantial uptake of 27-OHC by the brain, about 5 mg/24 
h ( 26 ), the steady-state levels within the brain are very low 
due to a rapid metabolism into a steroidal acid ( 27 ). This 
acid fl uxes from the brain into the circulation and is rap-
idly metabolized in the liver ( 27 ). Oxysterol 7  -hydroxylase 
(CYP7B1) seems to be the most critical enzyme in this con-
version. Similarly to CYP46A1, this enzyme seems to be ex-
clusively located to the neuronal cells.  Figure 1 summarizes 
the fl ux of oxysterols across the blood-brain barrier. 
 27-OHC is a potent inhibitor of cholesterol synthesis 
and has been shown to antagonize the benefi cial effects of 
24S-OHC to reducing amyloid accumulation in cultured 
neuronal cells ( 22 ). Based on this, we have suggested that 
 Fig.  1. Cross-talk of oxysterols across the blood-brain barrier 
( 3,27 ). 
 by guest, on O
ctober 8, 2019
w
w
w
.jlr.org
D
ow
nloaded from
 
2492 Journal of Lipid Research Volume 51, 2010
fective suppressor of the rate-limiting enzyme cholesterol 
7  -hydroxylase (CYP7A1) in humans ( 34 ). Thus, there is a 
marked upregulation of CYP7A1 in CTX, and the levels of 
7  -hydroxy-4-cholesten-3-one in the circulation may be in-
creased up to 100-fold ( 35 ). The latter steroid is able to 
pass the blood-brain barrier and may be converted into 
cholestanol in the brain ( 36 ). It is noteworthy that treat-
ment with chenodeoxycholic acid reverses the biochemi-
cal changes, and even the xanthomas in the brain may be 
reduced or disappear as a consequence of such treatment 
( 37 ). In some of the latter patients, the treatment with 
chenodeoxycholic acid was shown to improve cognition 
( 36 ). 
 The reason for the accumulation of cholesterol in 
parallel with cholestanol in the xanthomas is not clear. 
Cholestanol is, however, less effi cient than cholesterol in 
suppressing cholesterol synthesis ( 38 ), and a dilution of a 
cholesterol pool with cholestanol may cause a compensa-
tory increased synthesis of cholesterol. In some experi-
ments with experimental animals, dietary treatment with 
cholestanol has been shown to increase cholesterol syn-
thesis ( 39, 40 ). 
 In addition to formation of cholestanol, the accumula-
tion of 7  -hydroxylated intermediates in bile acid synthe-
sis leads to formation of 7  - and 25-hydroxylated alcohols, 
e.g., 5  -cholestane-3  ,7  ,12  ,25-tetrol. These alcohols 
may be secreted in bile and urine in gram amounts, and 
detection of these compounds is generally used in the di-
agnosis of the disease. 
 It is noteworthy that a disruption of the gene coding 
for the Cyp27a1 in mice does not lead to formation of 
xanthomas in tendons or brain ( 41 ). There is some ac-
cumulation of cholestanol in these structures, in particu-
lar in female mice, but this accumulation is less marked 
and is not accompanied by accumulation of cholesterol 
(Björkhem, unpublished observation). The reason for the 
difference between human CTX and the corresponding 
mouse model is not known with certainty. Part of the ex-
planation may be that the degree of upregulation of the 
CYP7A1 as a consequence of the lack of the CYP27A1 is 
less marked in the mouse model than in patients with 
CTX. 
 Hereditary spastic paresis type SPG5 
 Hereditary spastic paresis (HSP) is a genetically and 
clinically very heterogenous group of upper motor neuron 
degenerative diseases ( 42–46 ). The disease is character-
ized by selective axonal loss in the corticospinal tracts and 
dorsal columns. The cardinal features consist of progres-
sive spasticity of the lower limbs and muscle weakness, fre-
quently associated with deep sensory loss and urinary 
urgency. These features defi ne “pure” HSP, while “com-
plex” or “complicated” HSP are accompanied by other 
neurological signs such as ataxia, mental retardation, de-
mentia, visual dysfunction, and epilepsy. The different 
subgroups of HSP are associated with all modes of inheri-
tance and about 40 loci have been described. The fi rst 
pure autosomal-recessive HSP locus defi ned was called 
SPG5, located on chromosome 8q12.3. 
contain cholesterol, there is some production of 27-OHC 
in most cells. Because 27-OHC is able to pass cell mem-
branes, there is a continuous concentration-dependent 
fl ux of 27-OHC to the two organs containing effi cient me-
tabolizing systems, i.e., the liver and the brain. In the liver, 
27-OHC and its peripheral metabolites are further oxi-
dized into bile acids. The fl ux of 27-OHC and its metabo-
lites to the liver can be regarded as an alternative 
mechanism to the classical HDL-dependent reversed cho-
lesterol transport and may be regarded as antiatherogenic 
( 20, 32 ). In accordance with this, the levels of CYP27A1 
activity are particularly high in macrophages and endothe-
lial cells ( 20, 31 ). 
 The activity of CYP27A1 is dependent upon NADPH 
and the availability of two electron transporters, adreno-
doxin and adrenodoxin reductase ( 12 ). Additionally, it 
seems likely that specifi c transporters are required to trans-
port cholesterol to CYP27A1 on the inner mitochondrial 
membranes. At present, no mutation causing cerebroten-
dinous xanthomatosis (CTX) has been defi ned in any 
other protein than CYP27A1. There is, however, a descrip-
tion of a CTX patient with a heterozygous mutation in 
CYP27A1 who is likely to have a mutation in some addi-
tional protein, possibly a protein responsible for transport 
of cholesterol into the mitochondria ( 33 ). The possibility 
of an exon deletion was excluded. This subject has very 
low levels of 27-OHC in the circulation. Normally, subjects 
with a heterozygote mutation in the CYP27A1 gene have 
levels of 27-OHC about one-half those of normal and have 
no symptoms. 
 Currently, more than 300 CTX cases have been de-
scribed in the literature, with distinctive clusters in Japan, 
The Netherlands, and Israel. About 30 different mutations 
in the CYP27A1 gene have been described (missense, non-
sense, frameshift, and splice junction). 
 The activity of the enzyme is dependent upon a binding 
of the electron carrier adrenodoxin as well as binding of 
heme, and the mutations causing CTX are all located in 
the adrenodoxin binding or heme ligand binding sites 
( 31 ). Diagnosis of CTX is obtained by assay of 27-OHC, 
cholestanol, and bile alcohols in the circulation and MRI. 
Cholesterol levels are increased in the tissues but not in 
the circulation. The most serious consequence of the dis-
ease is the development of xanthomas in the brain and the 
neurological symptoms caused by this. The preferential 
site of the brain xanthomas is in the white matter of the 
cerebellum ( 30 ). 
 Generation of cholestanol is likely to be the driving 
force in this disease, and accumulation of cholesterol is 
likely to be secondary to this. Most of the excess cholestanol 
appears to be derived from 7  -hydroxylated intermediates 
during the synthesis of bile acids. Because CYP27A1 is re-
quired for oxidation of the steroid side chain in the nor-
mal biosynthesis of bile acids, there is an accumulation of 
7  -hydroxylated precursors to bile acids containing an in-
tact side chain, in particular 7  -hydroxy-4-cholesten-3-one 
( Fig. 2 ). This accumulation is further increased as a conse-
quence of the markedly reduced formation of the bile acid 
chenodeoxycholic acid. The latter bile acid is the most ef-
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 A disruption of the gene coding for Cyp7b1 in mice 
leads to accumulation of 27-OHC and 25-OHC in the cir-
culation, but otherwise the mice have no obvious pheno-
type ( 51 ). This is in contrast to the situation in humans; 
mice with a knockout of Cyp7b1 do not develop spastic 
paresis in spite of the elevated levels of 25-OHC and 27-
OHC. A transgenic mouse model overexpressing human 
CYP27A1 has also been developed and characterized ( 52 ). 
As with the Cyp7b1 knockout mice, the CYP27A1 trans-
genic mice have increased levels of 27-OHC, levels similar 
to those in Cyp7b1-defi cient mice. As with the Cyp27a1 
knockout mice, the CYP27A1 transgenic mice do not pres-
ent any obvious phenotype. 
 It may be concluded from the experiments with Cyp7b1-
defi cient and Cyp27a1-overxpressing mice that high levels 
of 25-OHC and 27-OHC are not suffi cient to cause obvious 
neurological defi cits. The situation is different in humans, 
however. The absolute plasma levels of the two SCOx are 
about 5-fold higher in patients with the SPG5 disease than 
in the above mouse models. Another factor that may be of 
importance is the relatively small corticospinal tract and its 
redundancy in rodents compared with humans ( 49 ). 
 Thus, we do not know if it is the high levels of the oxy-
sterols or the defective metabolism of neurosteroids that is 
the most important pathogenetic factor in patients with the 
SPG5 disease. SCOx such as 25-OHC and 27-OHC are known 
to be cytotoxic to cultured cells ( 20, 53 ). It has been reported 
that 25-OHC induces production of interleukin-1  and in-
terleukin-8 from human macrophages ( 54, 55 ) as well as al-
tering the production of IgA ( 56 ). We have discussed the 
possibility that a local interleukin release as a consequence 
of the high levels of 25-OHC may be a pathogenetic factor in 
the SPG5 patients ( 50 ). 
 The brains of patients with AD have reduced levels of 
CYP7B1 ( 57 ), probably as a consequence of the neuronal 
 Surprisingly, this locus was very recently identifi ed as 
the gene coding for the CYP7B1 ( 46 ). To date, more than 
20 unrelated, HSP-affected families with 17 different mu-
tations in the CYP7B1 gene have been described ( 42–46 ). 
Most patients with the SPG5 are “pure” with progressive 
lower limb spasticity as the only symptom, but a few of the 
patients can be regarded as “complicated” and also pres-
ent ataxia, mental retardation, and neurological symp-
toms. At this time, it is not known whether it will be possible 
to relate the site of the mutation and the degree of inhibi-
tion of the CYP7B1 activity to the clinical picture. 
 CYP7B1 is a 506 amino acid enzyme that catalyses the 
7  -hydroxylation of several steroids and SCOx [for a re-
cent review, see ( 47 )]. The enzyme is located in the endo-
plasmic reticulum and is dependent upon NADPH and 
cytochrome P-450 oxidoreductase for activity. The enzyme 
has a broad tissue distribution and is present in liver, kid-
ney, brain, and endocrine tissues. The substrate specifi city 
is broad and includes the two oxysterols 25-hydroxycholes-
terol (25-OHC) and 27-OHC ( 48 ). In addition, a number 
of C19 and C21-steroids, e.g., dehydroepiandrosterone 
and pregnenolone, are substrates for the enzyme ( 49 ). 
 CYP7B1 is evolutionarily conserved and is of importance 
both for bile acid synthesis and for metabolism of neuro-
steroids. Its role in bile acid synthesis is well defi ned, because 
the alternative pathway to bile acids starting with a 27-
hydroxylation of cholesterol as the fi rst step in the liver 
or in extrahepatic tissues is dependent on CYP7B1 ( 12 ). 
The metabolism of 27-OHC in the brain also requires 
CYP7B1 ( 27 ). The importance of CYP7B1 in connection 
with the turnover of the neurosteroids dehydroepiandro-
sterone and pregnenolone is less well defi ned. As antici-
pated, SPG5 patients have increased plasma levels of 27-
OHC (6- to 9-fold) and 25-OHC (100-fold) ( 50 ). A 30- to 50-
fold increase in 27-OHC was found in cerebrospinal fl uid. 
 Fig.  2. Metabolic relation between bile acid synthesis and formation of cholestanol in patients with CTX 
( 30, 36 ). 
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wild-type HTT is essential for normal embryonic develop-
ment, because knockout mutations to exons 4 or 5 or to the 
promoter results in embryonic lethality. HTT is widely ex-
pressed throughout the body, and it has been ascribed nu-
merous roles in various intracellular functions, including 
protein traffi cking, vesicle transport and anchoring, clath-
rin-mediated endocytosis, postsynaptic signaling, and tran-
scriptional regulation, as well as antiapoptotic function 
( 65 ). In the HD brain, particularly in striatum and cere-
bral cortex, an altered intracellular localization and peri-
nuclear accumulation of mutant HTT is observed, with the 
formation of neuronal intranuclear inclusions ( 66 ) and 
aggregates in dystrophic neurites ( 67 ). Such aggregates 
are considered the pathological hallmarks of HD and can 
be present in gene-positive premanifest subjects who are 
close to the estimated age-at-onset ( 68 ). 
 The expanded polyglutamine is thought to confer a new 
function to HTT that is toxic to the cell and impairs the 
correct function of the protein. The mutant protein tends 
to auto-aggregate and to promote aberrant protein-pro-
tein interactions in several subcellular locations ( 69 ), lead-
ing to the disruption of several intracellular pathways. The 
loss of function contributes to the disruption of intracel-
lular homeostasis, leading to neuronal dysfunction and 
death. The contribution of both toxic gain of function and 
loss of function of wild-type HTT culminates in neuronal 
dysfunction as an overall consequence of activation of pro-
tease, protein misfolding, transcriptional deregulation, 
proteasome impairment, oxidative injury, mitochondrial 
dysfunction, and disruption of axonal transport and syn-
aptic function ( 64 ). 
 A classic degenerative feature of HD is the gradual atro-
phy of the striatum (caudate nucleus and putamen) to-
gether with astrogliosis ( 70 ). The most affl icted neuronal 
populations are the medium-sized projection spiny neu-
rons, which correspond to 95% of the striatal neuronal 
population. Because these   -amino butyric acid-utilizing 
neurons are inhibitory, it is thought that the loss of their 
inhibition is the underlying cause of the uncontrolled 
movement characteristic of HD ( 71 ). According to MRI 
investigations, there is also a severe cortical atrophy com-
bined with striatal degeneration. The loss in brain mass is 
quite substantial in HD: during the 15–20 years of the dis-
ease course from the onset of symptoms to death, the brain 
weight declines in patients from an average of 1.350 g to 
<1.100 g ( 71 ). The clinical associates of such dramatic 
neurodegeneration, mainly occurring in the striatum and 
cortex ( 72 ), are progressive motor deterioration including 
chorea and dystonia. In addition there, are psychiatric and 
behavioral abnormalities, which may precede or accom-
pany the motor onset and cognitive decline ( 73 ). Neuro-
pathological fi ndings in HD are mirrored by evidence of 
progressive atrophy of the striatum on MRI scans ( 68 ). 
 The expression of some important genes involved in the 
cholesterol biosynthetic pathway, HMGCR, sterol 14-  
demethylase, and 7-dehydrocholesterol 7-reductase, is re-
duced in inducible mutant HTT cell lines as well as in stria-
tum and cortex from transgenic R6/2 HTT-fragment mice 
( 74 ). These changes are also present in brain and fi broblasts 
location of this enzyme and the neuronal loss in this dis-
ease. In accordance with this, the brains of these patients 
contain elevated levels of 27-OHC ( 58 ). The possibility has 
been discussed that this accumulation may be of some 
pathogenetic importance ( 28 ). If the accumulation of 25-
OHC and 27-OHC is the most important pathogenetic fac-
tor in the SPG5 disease, it may be benefi cial to reduce the 
levels of these oxysterols. Because it is known that substrate 
availability is a limiting factor for CYP27A1 activity, we have 
suggested that a possible therapeutic strategy could be to 
treat the patients with a cholesterol synthesis inhibitor 
( 50 ). Such treatment is thus known to reduce the levels of 
27-OHC in parallel with cholesterol. 
 HSP is, however, not the only pathological consequence 
of a mutation in the CYP7B1 gene. A decade before the link 
between SPG5 and CYP7B1 was reported, a fatal case with 
mutations in the CYP7B1 gene was reported, an infant who 
died in the neonatal stage with liver failure ( 59 ). Whether 
or not the mutation was causative or a contributing factor 
to the death of the infant is not known with certainty. The 
10-week-old boy presented with severe cholestasis, cir-
rhosis, and liver failure. The plasma levels of 27-OHC were 
increased more than 1,000 times those of normal controls, 
considerably higher than in adult patients with SPG5. An-
other oxysterol, 24S-OHC, was increased by a similar mag-
nitude in spite of the fact that this oxysterol is not a 
substrate for CYP7B1 ( 60 ). The latter fi nding suggests that 
other factors than the loss of the CYP7B1 activity must 
have contributed. More recently, another neonatal case 
was described with severe cholestatic liver disease, a muta-
tion in the CYP7B1 gene and a fatal outcome ( 61 ). The 
levels of oxysterols were never measured in this patient. To 
our knowledge, neonatal cholestasis has not been reported 
in any adult patient with the SPG5 disease. Thus, it seems 
likely that other factors than a CYP7B1 mutation must 
have contributed to the severe cholestasis in the two neo-
natal patients described thus far. The situation may be 
similar to that in patients with CTX. A few neonatal cases 
of this disease have been described with severe cholestasis 
( 62, 63 ). 
 Huntington’s disease 
 Huntington’s disease (HD) is an inherited dominant 
neurodegenerative disorder characterized by a glutamine 
expansion within the N terminus of the huntingtin pro-
tein (HTT) ( 64 ). It has a prevalence of 3–10 affected sub-
jects/100,000 individuals in Western Europe and North 
America. The CAG trinucleotide repeats is located within 
the coding region of exon 1 of the huntingtin gene, which 
is located on the short arm of chromosome 4 (4p63). 
 HTT is a protein composed of more than 3,100 amino 
acids with a molecular weight of about 349 kDa, depend-
ing on the exact number of glutamine residues. A poly-
morphic proline-rich segment follows the polyglutamine 
tail. Within the cell, wild-type HTT is mainly localized in 
the cytoplasm but is also associated with mitochondria, 
Golgi apparatus, endoplasmic reticulum, synaptic vesicles, 
and several components of the cytoskeleton. A small 
amount of HTT can also be found in the nucleus. The 
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ataxia, dysathria, dysphagia, tremor, and epilepsy. In the 
terminal stages, the patients have a loss volitional move-
ments and are severely demented. Mutations in the NPC 
type C1 (NPC1) and NPC type C2 (NPC2) specifi c genes 
have been identifi ed as the cause of the disease, with mu-
tations in NPC1 responsible for the vast majority (95%) of 
clinical cases ( 81 ). Unusually, despite very similar clinical 
manifestations, the NPC1 and NPC2 proteins are unre-
lated. NPC1 is a large membrane-anchored protein with 
homology to HMGCR, SREBP cleavage activating protein, 
and patched 1, a gene involved in Hedgehog signaling 
( 82, 83 ). In contrast, NPC2 is a small soluble glycoprotein 
( 81 ). The common clinical picture is thought to be a con-
sequence of the fact that both NPC1 and NPC2 partici-
pate in the movement of lipids, in particular cholesterol, 
out of the endolysosomal system. This has led to the con-
sensus that NPC disease is a cholesterol storage disease. 
NPC patients have a markedly impaired capacity for cho-
lesterol esterifi cation and accumulate free cholesterol, 
which may be directly observed by staining cultured fi bro-
blasts from the patients with fl uorescent probes such as 
fi lipin ( 84 ). The latter procedure is regarded to be the 
best diagnostic test. 
 As mentioned above, almost all cases of NPC disease 
arise from mutations in NPC1. NPC1 is a large (1,278 
amino acid) transmembrane protein with 13 putative 
membrane-spanning regions interspersed by various loops 
projecting into the lumen of endosomes or lysosomes 
( 82 ). There is signifi cant homology between helices 3-7 
and the so-called sterol sensing domain of other proteins 
involved in cholesterol turnover (SREBP cleavage acti-
vating protein and HMGCR) and hedgehog signaling 
(patched 1), indicating that there may be a common 
mechanism for sterol sensing. Using a photoactivable cho-
lesterol analog, Ohgami et al. ( 85 ) showed that sterol 
binding to NPC1 required a functional sterol sensing do-
main. More recent studies by Infante et al. ( 86 ) have con-
fi rmed and extended these observations. In an unbiased 
screen to identify a membrane-bound oxysterol binding 
protein, Infante et al. ( 86 ) reported , somewhat unexpect-
edly, that intact recombinant NPC1 was capable of binding 
SCOx as well as cholesterol. The highest affi nity binding 
occurred with 24S-, 25-, and 27-OHC. Notably, the authors 
reported that while SCOx were able to impair the binding 
of cholesterol, the reverse was not true, implying that there 
was more than one sterol binding site in the molecule and 
indeed suggesting that separate cholesterol and oxysterol 
binding sites are present ( 86 ). In a subsequent study, the 
same group defi ned a well-conserved, 240 amino acid loop 
region of NPC1 as the sterol binding site. Using a recom-
binant protein, these authors were able to demonstrate 
that sterol binding was saturable in this region, with a 13-
fold higher affi nity for 25-OHC compared with cholesterol 
( K d 10 nM vs. 130 nM, respectively), indicating that this is 
the oxysterol binding site on the protein ( 87 ). Because the 
brain contains about 0.1 mM levels of 24S-OH, it can be 
speculated that this site is largely saturated with this oxysterol 
under in vivo conditions. The potential functional role of 
such binding is impossible to evaluate with the present 
from HD patients ( 75 ). Additional studies showed that 
cholesterol synthesis and accumulation (as indicated by 
content of the cholesterol precursors lanosterol and 
lathosterol and by decreased enzymatic activity of HMGCR) 
are signifi cantly reduced in the brain of several rodent 
models such as the R6/2 mice, the yeast artifi cial chromo-
some mice, the ( Hdh Q111/111 )  Hdh knockin mice, and oth-
ers ( 76, 77 ) (Valenza and Leoni, unpublished observations). 
The degree of reduction of cholesterol synthesis and ac-
cumulation was found to increase with the length of the 
CAG repeats, the amount of mutated HTT, and age. Thus, 
the levels of cholesterol and precursors are only slightly 
reduced in young animals and much more reduced in 
older animals (Valenza and Leoni, unpublished observa-
tions). The molecular mechanism underlying this dysfunc-
tion appears to be a mutant HTT-dependent decrease in 
the amount of active gene coding for sterol regulatory ele-
ment binding protein (SREBP), resulting in less activation 
of SREBP-controlled genes. The molecular mechanism be-
hind the mutation in the huntingtin gene and the reduced 
level of SREBP is not known with certainty, however. 
 Interestingly, wild-type HTT is able to bind to nuclear 
receptors involved in lipid metabolism like LXR, PPAR  , 
and vitamin D receptor ( 78 ). Overexpression of HTT thus 
activates LXR, whereas in cells with a lack of HTT, there is 
an inhibition of LXR-mediated transcription. The possibil-
ity must be considered that in the case of HD, the mutated 
HTT is less able to upregulate LXR and LXR-targeted 
genes, including SREBP. Such a mechanism is a possible 
link between the HTT mutation and the disturbances in 
cholesterol metabolism. Further work is needed, however, 
to establish this. 
 Neurodegeneration, with loss of neurons, would be ex-
pected to lead to reduced levels of CYP46A1 with subse-
quent reduction in the formation of 24S-OHC and a lower 
effl ux from the brain to the circulation. In accordance 
with this, the 24S-OHC content was reduced in both brain 
and circulation of yeast artifi cial chromosome 128 mice 
( 76 ). In a large cohort of controls, HD patients and gene-
positive premanifesting patients, a signifi cant reduction of 
plasma levels in 24-OHC was observed in clinically mani-
festing patients. Notably, this reduction was correlated to 
the shrinking of striatum as estimated by MRI. In the case 
of preHD, it was found that patients closer to the onset of 
symptoms had levels similar to the HD stage 1 patients, 
and those far from onset had levels similar to those of con-
trols ( 79 ). It is likely that the observed reduction of choles-
terol turnover is a consequence of a loss of metabolically 
active neurons in brain. In a population of gene-positive, 
pre-HD individuals, we observed a reverse relationship be-
tween length of the CAG repeats and plasma levels of 24S-
OHC (Leoni, unpublished observations). 
 Niemann-Pick disease 
 Niemann Pick disease Type C (NPC) is a rare autosomal 
recessive neurovisceral lipid storage disease with no known 
cure ( 80 ). Progressive neurological disease is a hallmark 
and is responsible for disability and premature death be-
yond early childhood. The neurological symptoms include 
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NPC phenotype in cultured cells, Lloyd-Evans et al. ( 97 ) 
were able to show a very rapid (within 10 min) accumula-
tion of sphingosine followed by the accumulation of cho-
lesterol and other lipids. It should be noted, however, that 
U18666A may interact with many other proteins, compli-
cating the interpretation of this model. This compound is 
an inhibitor of oxidosqualene cyclase, a key enzyme in the 
synthesis of cholesterol ( 98 ). The authors speculated that 
the accumulation of sphingosine disturbs lysosomal cal-
cium homeostasis and leads to impaired vesicle traffi cking 
and fusion ( 97 ). Indeed, these authors report the accumu-
lation of sphingosine (3-fold) and sphingosine-1-phos-
phate (7-fold) in the brain of NPC1 null mice. Moreover, 
by treating the mouse model with a large dose of curcumin 
(150 mg/kg/day), a compound able to elevate cytosolic 
calcium levels, the authors were able to increase the life 
expectancy of the mice. It should be noted that S1P has 
recently been recognized as an endogenous histone 
deacetylase inhibitor and that by inhibiting CBP/p300 his-
tone acetyl transferase activity, curcumin is able to modu-
late gene expression ( 99 ). Given that there is accumulating 
evidence that sterol homeostasis is under epigenetic con-
trol, the proposed mechanistic explanation for the action 
of curcumin may not be the entire story ( 14, 15, 100 ). 
 A recent report indicates that the sphingosine analog 
FTY720 can stimulate formation of 27-OHC and activate 
LXR ( 101 ). This implies that enhanced formation of SCOx 
may be a general mechanism engaged to reduce choles-
terol in the endolysosomal system. The recent recognition 
that the STARt domain containing protein MLN64 is able 
to promote movement of cholesterol to the mitochondria 
(the site of 27-OHC formation) in the absence of func-
tional NPC1 adds weight to the concept that formation of 
27-OHC is a compensatory mechanism ( 102 ). Very recent 
data on the levels of 27-OHC in the plasma of NPC1 null 
mice has provided some support for this; these levels are 
markedly elevated ( 103 ). However, given the role of 
CYP7B1 in the metabolism of 27-OHC, it cannot be ex-
cluded that metabolism is impaired rather than synthesis 
increased. In contrast, cultured fi broblasts from NPC pa-
tients have a decreased level of 27-OHC ( 104, 105 ). 
 The very recent report on the effectiveness of cyclodex-
trin therapy further supports the role of cholesterol rather 
than sphingosine as the pathogenic factor. Treatment of 
NPC1 knockout mice with cyclodextrin effectively over-
came the transport defect in NPC disease and led to excre-
tion of cholesterol (as bile acids) from the affected mice, 
with the exception of the lungs ( 106 ). Early treatment (7 
days postnatally) resulted in a signifi cant increase in the 
lifespan of the affected animals ( 107 ). A human trial of 
this therapy is currently underway. 
 Very recent data has been presented indicating that the 
plasma concentration of certain oxysterols, in particular 
the auto-oxidation products 7-oxocholesterol and choles-
tane 3,5,6-triol, is elevated in NPC disease, indicating a pos-
sible role for measurement of these sterols in the diagnosis 
and/or monitoring of NPC disease ( 103, 108 ). These data 
are consistent with the previous demonstration by Alvelius 
et al. ( 109 ) that the urine of an NPC patient contains unusual 
knowledge, although it is possible that it may infl uence 
cholesterol supply to the ER, where 24S-OHC is synthe-
sized. Emerging studies have indicated that the expression 
of NPC1mRNA and protein are regulated by LXR both in 
vitro and in vivo. Oxysterols such as 24S-OHC ( 86–88 ) are 
thought to be responsible for the activation in vivo. In this 
connection, it is of interest that treatment with LXR ago-
nists increased the lifespan of NPC null mice ( 89 ). In the 
brain in particular , the convergence of different pathways 
on the 24S-OHC underscores the importance of this me-
tabolite for brain cholesterol homeostasis. 
 In contrast to NPC1, NPC2 is a small (132 amino acid) 
soluble glycoprotein present in both the lysosomes and in 
various secreted fl uids [to date, NPC2 has been identifi ed 
in milk, epididymal fl uid, plasma, and bile ( 88–90 )]. The 
structure of NPC2 has been determined, and functional 
studies have confi rmed that the loosely packed hydropho-
bic core is an authentic cholesterol binding pocket and 
that NPC2 binds cholesterol with low micromolar binding 
affi nities ( 91 ). Available data indicate that cholesterol is 
oriented such that the 3  -hydroxy group is at the entrance 
to the binding site, and the remainder of the hydrophobic 
cholesterol molecule is buried within the NPC2. Notably, 
it has also been shown using competition assays that SCOx 
are unable to bind to NPC2 ( 92 ). Despite the clear data on 
cholesterol binding to NPC2, studies have shown that al-
though some point mutations do not signifi cantly affect 
the capacity for cholesterol binding, they do impair the 
ability of exogenous NPC2 to correct NPC2 defi ciency in 
cell systems. It has been proposed that NPC2 facilitates the 
rapid movement of cholesterol between lipid bilayers to 
NPC1, providing a plausible explanation for how muta-
tions in either of these unrelated proteins may lead to 
clinical manifestations of the disease ( 93 ). 
 Accumulation of free cholesterol in tissues is a consis-
tent fi nding in NPC patients, including the brain ( 94 ), 
where cholesterol may also be redistributed within indi-
vidual neurons ( 95 ). It should be noted that the extremely 
long half-life of the majority of brain cholesterol has ob-
scured the direct identifi cation of cholesterol accumula-
tion using analytical biochemical methods. However, using 
fi lipin microfl uorodensitometry, Treiber-Held et al. ( 94 ) 
demonstrated a signifi cant accumulation of cholesterol in 
the brains of NPC1 null mice, with the cholesterol accu-
mulating before the onset of a disease phenotype. A con-
sequence of cholesterol accumulation of this is that the 
neurons become distorted; NPC patients often have ecto-
pic dendrite formation and neurofi brillary tangles similar 
to those see in AD ( 96 ). The Purkinje cells of the cerebel-
lum seem particularly vulnerable to the effects of choles-
terol accumulation, perhaps related to the capacity of the 
cerebellum to synthesize cholesterol. 
 In addition to cholesterol, several other lipids have been 
found to accumulate in NPC disease, most notably sphin-
gomyelin in the periphery and glycosphingolipids in the 
brain (for details, see the review from Xu et al. in this The-
matic Series). Very recently, it was proposed that the earli-
est defect in NPC disease is accumulation of sphingosine 
( 97 ). Using the class II amphiphile U18666A to induce 
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AD ( 118, 119 ). The most important cholesterol-associated 
risk factor is, however, presence of the   4 isoform of the 
cholesterol transporter APOE [for reviews, see ( 120, 121 )]. 
In addition, recent genome wide association studies have 
provided compelling evidence that genetic variations in 
APOJ are associated with the risk of developing AD ( 122–
124 ). However, the precise mechanistic connection(s) be-
tween these genes and AD remain poorly described. This 
is made all the more diffi cult by the fact that current data 
indicates a role for APOE in both brain sterol balance and 
clearance of   -amyloid ( 125 ). Regardless of the specifi c 
role of APOE (and possibly APOJ) in   -amyloid metabo-
lism, it is evident that there must be signifi cant overlap 
with pathways governing cholesterol balance, and expres-
sion of APOE is known to be regulated by cholesterol. 
 The concentration of cholesterol in the critical mem-
branes is of importance for the balance between   - and 
  -secretase activity, with consequences for the rate of gen-
eration of amyloid ( 126 ). Both APP and A  are at least in 
part associated with cholesterol-rich domains and in-
creased concentrations of cholesterol leads to increased 
production of A  . Conversely, however,   -amyloid may 
affect cholesterol synthesis or effl ux and the concentra-
tion of cholesterol in the membranes ( 127, 128 ). Thus, 
it is possible that there is a negative feedback cycle in 
which increased cholesterol increases production of A  
that in turn inhibits cholesterol synthesis. Under some 
conditions, this balance may, however, be disrupted with a 
switching toward the amyloidogenic pathway. Also, the 
state of   phosphorylation is affected by cholesterol levels 
in the lipid rafts, with reduced cholesterol stimulating 
phosphorylation ( 129 ). 
 A detailed description of the great number of different 
factors involved in neurodegeneration possible to modu-
late by cholesterol is, however, beyond the scope of this 
article. Here, we focus on two established genetic risk fac-
tors for AD: hypercholesterolemia and presence of the   4 
isoform of APOE. 
 Hypercholesterolemia as a risk factor for AD 
 Hypercholesterolemia is a risk factor not only for ath-
erosclerosis but also for AD. Increased cholesterol levels in 
midlife have been linked to AD-type pathology in autopsy 
studies ( 130, 131 ). Treatment of rabbits and mice with 
cholesterol-enriched diets has been reported to result in 
cerebral accumulation of amyloid ( 132, 133 ). The highly 
unphysiological conditions used for the animal experi-
ments makes it diffi cult, however, to draw fi rm conclu-
sions. In a recent study, it was found that the induction of 
AD-like neuropathology by dietary cholesterol depends on 
the quality of the water that the animal was drinking 
( 134 ). 
 In view of the fact that lipoprotein-bound cholesterol in 
the circulation does not pass the blood-brain barrier un-
der normal conditions, it is diffi cult to understand the 
mechanism by which hypercholesterolemia increases the risk 
for neurodegeneration. We have suggested that the oxy-
sterol 27-OHC could be a link between hypercholester-
olemia and neurodegeneration ( 28, 29 ). In contrast to 
7-oxygenated bile acid sulfates, possibly representing the 
elimination product of 7-oxocholesterol. It is diffi cult to 
understand the origin of these sterols, which are likely to 
be formed by autooxidation rather than by enzymes. It has 
been reported that ferritin is defi cient in NPC disease, sug-
gesting a block in iron homeostasis and an inability to cor-
rectly store iron, which is consistent with the known pathway 
for the internalization of transferrin ( 110, 111 ). Because 
iron is known to be able to catalyze the formation of oxy-
sterols from cholesterol via the Fenton reaction, it is fea-
sible that the accumulation of cholesterol leads to the 
expansion of a pool of substrate for this reaction in vivo in 
conjunction with iron accumulation. Chodhury et al. ( 112 ) 
have demonstrated that increased membrane cholesterol 
disturbs the endolysosomal pathway in a general sense, 
which would be anticipated to impair the transfer of iron 
from transferring to ferritin. Moreover, transcriptomic 
studies have indicated that there is a modest increase in the 
expression of genes involved in oxidative stress in NPC 
cells, proving some support for this idea ( 113 ). 
 CHOLESTEROL AND AD 
 AD is a devastating neurodegenerative disorder. In the 
Western population, it has been estimated that about 10% 
of the population over the age of 65 years and one-half 
those over age 85 years have AD ( 114, 115 ). The most 
important characteristic of AD pathology is the presence 
of extracellular   -amyloid containing senile plaques and 
  -protein containing neurofi brillary tangles in the neuronal 
cells. In rare cases of familiar forms of AD, three distinct 
genes have been identifi ed that are of importance for gen-
eration of amyloid: the APP gene and the presenilin 1 and 
presenilin 2 genes. Mutations in these genes result in over-
production of amyloid   (A  )-peptides or the proportion 
of the longer A  42 form. The longer form is regarded to 
be more amyloidogenic and toxic than the shorter form 
due to its highly aggregative nature ( 116 ). The clinical 
consequences of the mutations in the above genes have 
led to the “amyloid hypothesis” according to which in-
creased synthesis or decreased degradation of A  is the 
most important factor behind the neuroinfl ammation, 
neurodegeneration, memory loss, and senile dementia in 
AD ( 116 ). In addition to the amyloid-containing plaques, 
oligomers of A  in the cytoplasm of neurons are thought 
to be important for the pathogenesis. 
 Except for the rare cases with a defi ned mutation in one 
of the above critical genes (<2% of the patients), AD is a 
multifactoral disease. It is possible that the amyloid cascade 
is not always the driving force and there is an imperfect 
histopathological correlation of plaque deposition on one 
hand and neuronal loss and dementia on the other hand. 
At present, the possibility cannot be excluded that AD of-
ten is a consequence of a disruption of more fundamental 
cellular functions that, when impaired, kill neuronal cells 
and promote plaque formation in the process ( 117 ). 
 Hypercholesterolemia in mid-life is one of several fac-
tors associated with a moderately increased risk to develop 
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the E4/4 genotype carries about 15 times the risk of the 
60% of the population that has the E3/3 genotype. It has 
been reported that no APOE4/4 carrier has been shown 
to reach the age 90 without having AD ( 139 ). 
 From a structural point of view, the difference among 
the three isoforms is minor, involving only two amino 
acid positions [E2 (cys 112 ,cys 158 ), E3 (cys 112 ,arg 158 ), and E4 
(arg 112 ,arg 158 )]. 
 These changes affect the three-dimensional structure as 
well as the lipid binding properties of the isoforms. Thus, 
APOE3 and APOE2 preferentially bind HDL, whereas 
APOE4 preferentially binds VLDL. It is likely that this 
change will affect the capacity of APOE to participate in 
the distribution of lipids necessary for proliferation, synap-
togenesis, and myelinization of axons. It important to note 
that humans are the only species that has arg61 in APOE, 
which leads to domain interaction as a second layer of 
structural complexity. 
 The evolutionary history of APOE genotypes in humans 
is unique and has been proposed to be a result of adaptive 
changes ( 120, 121 ). According to current concepts, the 
APOE4 allele is the ancestral gene, existing alone until 
300,000 years ago, at which time the APOE3 allele ap-
peared. The APOE2 allele mutated from the E3 allele 
about 200,000 years ago. Introduction of the new APOE 
genotypes provided better cognitive and cardiovascular 
function to those rare subjects who survived beyond 60 
years of age at that time. The retention of more elderly 
subjects with intact cognitive function in the population 
may have been important for accumulation of knowledge 
and expansion of human populations ( 139 ). 
 A great number of studies have appeared demonstrat-
ing that the association of APOE4 to AD affects the major-
ity of the pathological events in AD (A  -generation and 
deposition, formation of neurofi brillary tangles, neuronal 
survival, lipid homeostasis, intracellular signaling) ( 121 ). 
With respect to A  -generation, APOE4 has been shown to 
stimulate endocytic recycling of APP, resulting in increased 
net production ( 140 ). In contrast to APOE4, APOE3, and 
APOE2 seem to have a protective role by inhibiting A  ag-
gregation and/or favoring A  -clearance ( 141 ). 
 Under in vitro conditions, APOE3 but not APOE4 forms 
a stable complex with   . Phosphorylation of   inhibits its 
interaction with APOE3, suggesting that APOE3 only binds 
to nonphosphorylated   . Based on this, it has been sug-
gested that APOE3 might be able to prevent the abnormal 
hyperphosphorylation occurring in AD and the destabili-
zation of the neuronal cytoskeleton ( 142 ). The carboxy 
terminal-truncated form of APOE4 is neurotoxic and stim-
ulates   phosphorylation ( 143 ). The enzymatic cleavage of 
APOE to give the carboxy-terminal truncated form may 
thus be important, and it has been shown that the serin 
protease involved in this hydrolysis cleaves APOE4 more 
effi ciently than APOE3. The APOE fragments are generated 
inside cultured neuronal cells and in AD brains and may 
interact with phospho-  and phosphorylated neurofi laments 
of high molecular weight, resulting in large fi lamentous 
intracellular inclusions in the neuronal cells ( 144 ). Stud-
ies with transgenic mice have shown increased phosphory-
cholesterol, 27-OHC passes the blood-brain barrier and 
there is a positive correlation between levels of cholesterol 
and 27-OHC in the circulation ( 135 ). Thus, it is likely that 
hypercholesterolemia leads to a higher uptake of 27-OHC. 
The latter steroid has been shown to antagonize the pre-
ventive effect of 24S-OHC on generation of amyloid under 
in vitro conditions ( 22, 23 ). In addition, 27-OHC has a 
downregulating effect on the “memory protein” activity-
regulated cytoskeleton-associated protein in mouse brain 
( 136 ). The same effect is obtained by treatment of the 
mice with a cholesterol-enriched diet, consistent with the 
possibility that 27-OHC is the link between the hypercho-
lesterolemia and the effect. Further studies are needed, 
however, to clarify this. 
 If high cholesterol in the circulation is a pathogenetic 
factor in AD, a lowering of these levels may be benefi cial. 
In view of the fact that hypercholesterolemia increases the 
risk for AD by a factor of about 2 ( 119, 121 ), only relatively 
small effects can be expected after treatment with lipid-
lowering drugs. A great number of clinical studies of dif-
ferent design have been performed with statins [for a 
review see ( 137 )]. Several of these studies have shown a 
positive effect ,whereas others have been negative. Two 
large, very well-designed, double-blind, randomized, pla-
cebo-controlled trials of statins in people at risk for de-
mentia were, however, negative ( 138 ) and at present it is 
not possible to conclude that statins have a protective ef-
fect on AD. 
 Role of APOE and its different isoforms in AD and other 
neurodegenerative diseases 
 The strongest risk factor known for nonfamiliar AD is 
the genotype for the cholesterol transporter APOE [for 
general and more detailed reviews, see ( 120, 121 )]. The 
fact that the ApoE genotype might account for at least 
50% of AD in a Caucasian population is one of the most 
obvious indications of the importance of cholesterol 
homeostasis for development of a neurodegenerative dis-
ease. It should be emphasized, however, that given the 
pleiotrophic physiological functions of APOE, part of the 
genetic association with neuropathological disease may be 
unrelated to the known role of the protein in cholesterol 
metabolism. 
 APOE, a 34 kDa protein composed of 299 amino acids, 
is the most important lipoprotein for uptake of lipopro-
teins by the LDL receptor, the LDL receptor related pro-
tein, the APOE receptor 2, the VLDL receptor, and 
megalin ( 119, 120 ). In humans, the APOE gene shows 
polymorphism with three different alleles (E2, E3, and 
E4) that gives rise to six different phenotypes (E2/2 , E2/3, 
E2/4, E3/3, E3/4, E4/4). APOE3 is the most common iso-
form (77–78%), while APOE2 is found in 7–8% and APOE4 
in 14–16% in most Western populations. Subjects with one 
or two copies of APOE4 have a higher risk of developing 
AD compared with carriers of other isoforms. APOE also 
reduces the median age for AD onset from 84 in noncarri-
ers to 68 in E4 homozygotes. The E4 allele occurs in about 
60% of AD patients (about 15% with E4/4, 40% with E3/4, 
and <5% with APOE2/4). The 2% of the population with 
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 Schommer , and  O.  Ghribi .  2009 .  Differential effects of 24-
hydroxycholesterol and 27-hydroxycholesterol on beta-amyloid 
precursor protein levels and processing in human neuroblastoma 
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 et al .  2010 .  Adeno-associated virus gene therapy with cholesterol 
24-hydroxylase reduces the amyloid pathology before or after the 
onset of amyloid plaques in mouse models of Alzheimer’s disease. 
 Mol. Ther.  18 :  44 – 53 . 
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 E.  Rousselet ,  N. G.  Seidah ,  S.  Oddo ,  F. M.  LaFerla ,  T. A.  Spencer , 
 et al .  2010 .  ACAT1 gene ablation increases 24(S)-hydroxycholesterol 
content in the brain and ameliorates amyloid pathology in mice 
with AD.  Proc. Natl. Acad. Sci. USA .  107 :  3081 – 3086 . 
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lation of   in mice expressing human APOE4 in neurons, 
but not in mice expressing this protein in astrocytes ( 145 ). 
The effect of APOE4 thus seems to be specifi c for neu-
ronal cells. 
 Induction of APOE synthesis by neuronal cells has been 
suggested to protect them from injury or to promote intra-
neuronal repair and maintenance of synapto-dendritic 
connections ( 121 ). When synthesized by neurons, how-
ever, the above-mentioned serine protease is also active 
and cleaves APOE, resulting in fragments that are detri-
mental to the repair/maintenance process. Because of its 
conformation and reactivity, APOE4 is more sensitive to 
cleavage than APOE3. 
 Cholesterol uptake by cultured neuronal cells is lower 
when the lipid is bound to APOE4 compared with APOE2 
and APOE3 ( 146 ). APOE4 is less effi cient than the other 
forms to stimulate cholesterol effl ux from astrocytes and 
neuronal cells. Experiments with transgenic mouse mod-
els in which the murine APOE has been replaced with hu-
man APOE4 or APOE3 have shown that APOE4 but not 
APOE3 transgenic mice have an age-dependent disrup-
tion of synaptic organization ( 147 ). It has been shown in 
humans that APOE4 carriers show a poor compensation of 
neuronal loss in different brain regions, whereas non-E4 
carriers exhibit marked regenerative changes in the same 
areas ( 120, 148 ). 
 In all the above cases, the presence of APOE4 is either 
negative or does not have a positive effect in relation to 
that of other isoforms. The negative effect is, however, not 
restricted to AD, as the presence of APOE4 has also nega-
tive effects on other neurological diseases, including 
stroke, severity of head trauma, Parkinsons’s disease, amyo-
trophic lateral sclerosis, multiple sclerosis, Lewy body dis-
ease, and CNS ischemia [for a detailed review, see ( 121 )]. 
Thus, it is tempting to suggest that APOE might partici-
pate in molecular mechanisms that are common to several 
disorders ( 120, 121 ).  
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